EUVIMEDEUVIMED entdecken
Open Access

Real-World Experience with 177 Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval

Abuzar Moradi Tuchayi, Surekha Yadav, Fei Jiang, Sarasa T Kim, Rachelle K Saelee, Amanda Morley, Roxanna Juarez, Courtney Lawhn-Heath, Yingbing Wang, Ivan de Kouchkovsky, Thomas A Hope

Journal of Nuclear Medicine · 2024-05 · 65 (5) · 735-739

DOI: 10.2967/jnumed.123.266842 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 14.03.2024. Verfasst von Abuzar Moradi Tuchayi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California. Hauptthemen laut MEDLINE: Lutetium, Heterocyclic Compounds, 1-Ring, Dipeptides, United States Food and Drug Administration. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report our initial real-world experience with 177Lu-PSMA-617 radioligand therapy.

Methods

We performed a retrospective review of patients treated with 177Lu-PSMA-617. Pretreatment PSMA PET, laboratory findings, overall survival, a fall in prostate-specific antigen by 50% (PSA50), and toxicities were evaluated.

Results

Ninety-nine patients were included. Sixty patients achieved a PSA50. Seven of 18 (39%) patients who did not meet the TheraP PSMA imaging criteria achieved a PSA50. Nineteen of 31 (61%) patients who did not meet the VISION laboratory criteria achieved a PSA50. Sixty-three patients had a delay or stoppage in therapy, which was due to a good response in 19 patients and progressive disease in 14 patients. Of 10 patients with a good response who restarted treatment, 9 subsequently achieved a PSA50 on retreatment. The most common toxicities were anemia (33%) and thrombocytopenia (21%).

Conclusion

At our center, patients who did not meet the TheraP PSMA imaging criteria or the VISION laboratory criteria benefited from 177Lu-PSMA-617 radioligand therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LutetiumHeterocyclic Compounds, 1-RingDipeptidesUnited States Food and Drug AdministrationHumansMaleAgedRetrospective StudiesMiddle AgedUnited StatesProstate-Specific AntigenAged, 80 and overDrug ApprovalLigandsTreatment OutcomeProstatic NeoplasmsRadiopharmaceuticals

Stichwörter der Autor:innen

177Lu-PSMA-617genitourinaryoncologyradionuclide therapytoxicities

Substanzen

LutetiumPluvictoHeterocyclic Compounds, 1-RingDipeptidesProstate-Specific AntigenLigandsRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.
  • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California; and.
  • Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
  • Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu.

Förderung

  • NCI NIH HHS

Zitieren

APA

Moradi Tuchayi, A., Yadav, S., Jiang, F., Kim, S. T., Saelee, R. K., Morley, A., Juarez, R., Lawhn-Heath, C., Wang, Y., de Kouchkovsky, I., & Hope, T. A. (2024). Real-World Experience with 177 Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval. Journal of Nuclear Medicine, 65(5), 735-739. https://doi.org/10.2967/jnumed.123.266842

Vancouver

Moradi Tuchayi A, Yadav S, Jiang F, Kim ST, Saelee RK, Morley A, et al. Real-World Experience with 177 Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval. Journal of Nuclear Medicine. 2024;65(5):735-739. doi:10.2967/jnumed.123.266842

BibTeX
@article{MoradiTuchayi2024,
  author = {Moradi Tuchayi, Abuzar and Yadav, Surekha and Jiang, Fei and Kim, Sarasa T and Saelee, Rachelle K and Morley, Amanda and Juarez, Roxanna and Lawhn-Heath, Courtney and Wang, Yingbing and de Kouchkovsky, Ivan and Hope, Thomas A},
  title = {Real-World Experience with 177 Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {5},
  pages = {735--739},
  doi = {10.2967/jnumed.123.266842}
}
Kostenlos starten →